The latest news and information about what's going on with SCI science and research.
One of the bigger questions raised during the Interdependence 2012 Global Spinal Cord Injury Conference held last week in Vancouver: If clinical trials are so hard, so expensive, so tricky to get approved, and so prone to failure, what are the best chances to succeed the next time a trial is planned related to spinal cord injury?
Read More
Vancouver – Day two of the Interdependence 2012 Global Spinal Cord Injury Conference. In between sessions at the moment; first, a few things to catch up on from Tuesday.
Read More
Vancouver, BC. – I’m attending the Interdependence 2012 Global SCI Conference this week and this is the first of several blogs about the meeting. The event is part of the 25th anniversary celebration for Rick Hansen, the Canadian paraplegic who wheeled nearly 25,000 miles across 34 countries way back when and raised $26 million for spinal cord injury research and accessibility. Read More
News came late last month of a new clinical trial for acute spinal cord injury. Asubio Pharmaceuticals, based in New Jersey, a small subsidiary of Daiichi Sankyo, a large Japanese pharma company, announced a 164-patient Phase II randomized, placebo-controlled trial for its molecule
SUN13837, which will be administered to persons with C4 to C7 injuries within 12 hours after injury, in U.S. and Canadian trauma centers.
Read More
